Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 ProBioGen Licenses GlymaxX Technology to Bayer | Contract Pharma

What are you searching for?

Sign in
Breaking News

ProBioGen Licenses GlymaxX Technology to Bayer

Will leverage the technology to further increase the potency of an undisclosed antibody candidate for oncology indications

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

ProBioGen AG, a service and technology provider for complex therapeutic antibodies and glycoproteins, has entered a license agreement with Bayer AG for the  GlymaxX Technology. Under the agreement, Bayer will leverage the technology to further increase the potency of an undisclosed antibody candidate for oncological indications.

ProBioGen’s antibody-dependent cellular cytotoxicity (ADCC) enhancing technology GlymaxX will be applied during cell line development.

“We are glad to add Bayer to our list of licensees”, said ProBioGen’s Chief Executive Officer Dr. Wieland Wolf. “The GlymaxX® technology is clinically proven and is a very flexible technology which is liked by all cell lines.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics